Irritable bowel syndrome with diarrhea: How INSL5 hormone targeting offers new treatment hope

Recent research identifies Insulin-Like Peptide 5 (INSL5) as a key contributor in many Irritable bowel syndrome with diarrhea cases, offering a new target for treatment. Elevated INSL5 levels are linked to chronic diarrhea, influencing intestinal motility and fluid secretion. Targeting this hormone could lead to more precise diagnostics and effective therapies, improving symptom control and quality of life for patients.